COVID-19 is now underway in Edmonton and Calgary.In the trial, convalescent plasma is taken from patients who have recovered from COVID-19.
That plasma, which contains antibodies to the virus, is then transferred to patients who are being hospitalized for the illness but have not yet been intubated.“Providing these passive antibodies to patients, we hope will improve their survival and actually prevent them from developing severe disease,” said Dr.
Wendy Sligl, a co-investigator in the clinical trial. She is also an infectious diseases and critical care physician at the University of Alberta Hospital.The convalescent plasma trial, also called CONCOR, is being coordinated nationwide by the Canadian Blood Services and is being overseen in.